Decreasing antibiotic resistance of Enterobacteriaceae by introducing a new antibiotic combination therapy for neutropenic fever patients View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1998-10-01

AUTHORS

J Mebis, H Goossens, P Bruyneel, JP Sion, I Meeus, J Van Droogenbroeck, W Schroyens, ZN Berneman

ABSTRACT

Prompt empiric antibiotic therapy is of critical importance for patients with neutropenic fever. However, a major concern with important clinical consequences is the emergence of bacterial resistance to antibiotics. After using ceftazidime with a glycopeptide as initial empiric therapy for neutropenic fever, we were confronted with a 75% reduced susceptibility rate to ceftazidime of inducible Enterobacteriaceae collected in 1994. The initial empiric therapy was therefore replaced in May 1995 by a combination of cefepime with amikacin, with addition of a glycopeptide after 48 h if necessary. After this change, we observed a significant decrease in reduced susceptibility of inducible Enterobacteriaceae, not only to ceftazidime, but also to amikacin, cotrimoxazole and ciprofloxacin. There was also a decrease in reduced susceptibility of non-inducible Enterobacteriaceae, such as Klebsiella spp, to ceftazidime. The reduction of resistance may be related at least in part to the combined use of cefepime together with an aminoglycoside. This study shows that it is possible to reverse bacterial resistance by modifying the antibiotic regimen used. More... »

PAGES

1627-1629

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.leu.2401158

DOI

http://dx.doi.org/10.1038/sj.leu.2401158

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1044691809

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/9766509


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Amikacin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cefepime", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ceftazidime", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cephalosporins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Microbial", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enterobacteriaceae", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enterobacteriaceae Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fever", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hematologic Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Microbial Sensitivity Tests", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neutropenia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Teicoplanin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vancomycin", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Hematology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium", 
          "id": "http://www.grid.ac/institutes/grid.411414.5", 
          "name": [
            "Division of Hematology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mebis", 
        "givenName": "J", 
        "id": "sg:person.0773342364.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773342364.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Laboratory of Microbiology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium", 
          "id": "http://www.grid.ac/institutes/grid.411414.5", 
          "name": [
            "Laboratory of Microbiology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goossens", 
        "givenName": "H", 
        "id": "sg:person.0711125233.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711125233.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Central Pharmacy, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium", 
          "id": "http://www.grid.ac/institutes/grid.411414.5", 
          "name": [
            "Central Pharmacy, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bruyneel", 
        "givenName": "P", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hospital Hygiene, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium", 
          "id": "http://www.grid.ac/institutes/grid.411414.5", 
          "name": [
            "Division of Hospital Hygiene, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sion", 
        "givenName": "JP", 
        "id": "sg:person.01107322752.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01107322752.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium", 
          "id": "http://www.grid.ac/institutes/grid.411414.5", 
          "name": [
            "Division of Hematology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Meeus", 
        "givenName": "I", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium", 
          "id": "http://www.grid.ac/institutes/grid.411414.5", 
          "name": [
            "Division of Hematology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Van Droogenbroeck", 
        "givenName": "J", 
        "id": "sg:person.01056520727.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01056520727.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium", 
          "id": "http://www.grid.ac/institutes/grid.411414.5", 
          "name": [
            "Division of Hematology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schroyens", 
        "givenName": "W", 
        "id": "sg:person.0653223122.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653223122.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium", 
          "id": "http://www.grid.ac/institutes/grid.411414.5", 
          "name": [
            "Division of Hematology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Berneman", 
        "givenName": "ZN", 
        "id": "sg:person.0715102045.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0715102045.57"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1998-10-01", 
    "datePublishedReg": "1998-10-01", 
    "description": "Prompt empiric antibiotic therapy is of critical importance for patients with neutropenic fever. However, a major concern with important clinical consequences is the emergence of bacterial resistance to antibiotics. After using ceftazidime with a glycopeptide as initial empiric therapy for neutropenic fever, we were confronted with a 75% reduced susceptibility rate to ceftazidime of inducible Enterobacteriaceae collected in 1994. The initial empiric therapy was therefore replaced in May 1995 by a combination of cefepime with amikacin, with addition of a glycopeptide after 48\u2009h if necessary. After this change, we observed a significant decrease in reduced susceptibility of inducible Enterobacteriaceae, not only to ceftazidime, but also to amikacin, cotrimoxazole and ciprofloxacin. There was also a decrease in reduced susceptibility of non-inducible Enterobacteriaceae, such as Klebsiella spp, to ceftazidime. The reduction of resistance may be related at least in part to the combined use of cefepime together with an aminoglycoside. This study shows that it is possible to reverse bacterial resistance by modifying the antibiotic regimen used.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.leu.2401158", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1097065", 
        "issn": [
          "0887-6924", 
          "1476-5551"
        ], 
        "name": "Leukemia", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "keywords": [
      "initial empiric therapy", 
      "inducible Enterobacteriaceae", 
      "neutropenic fever", 
      "empiric therapy", 
      "prompt empiric antibiotic therapy", 
      "reduced susceptibility rates", 
      "neutropenic fever patients", 
      "reduced susceptibility", 
      "empiric antibiotic therapy", 
      "combination of cefepime", 
      "use of cefepime", 
      "antibiotic combination therapy", 
      "important clinical consequences", 
      "bacterial resistance", 
      "antibiotic regimen", 
      "antibiotic therapy", 
      "combination therapy", 
      "fever patients", 
      "clinical consequences", 
      "susceptibility rates", 
      "Klebsiella spp", 
      "therapy", 
      "ceftazidime", 
      "significant decrease", 
      "antibiotic resistance", 
      "patients", 
      "fever", 
      "amikacin", 
      "cefepime", 
      "Enterobacteriaceae", 
      "cotrimoxazole", 
      "regimen", 
      "susceptibility", 
      "aminoglycosides", 
      "ciprofloxacin", 
      "antibiotics", 
      "resistance", 
      "decrease", 
      "reduction of resistance", 
      "glycopeptides", 
      "major concern", 
      "critical importance", 
      "study", 
      "rate", 
      "reduction", 
      "changes", 
      "spp", 
      "use", 
      "combination", 
      "concern", 
      "addition", 
      "consequences", 
      "importance", 
      "emergence", 
      "part"
    ], 
    "name": "Decreasing antibiotic resistance of Enterobacteriaceae by introducing a new antibiotic combination therapy for neutropenic fever patients", 
    "pagination": "1627-1629", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1044691809"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.leu.2401158"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "9766509"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.leu.2401158", 
      "https://app.dimensions.ai/details/publication/pub.1044691809"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:20", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_268.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.leu.2401158"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2401158'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2401158'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2401158'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2401158'


 

This table displays all metadata directly associated to this object as RDF triples.

233 TRIPLES      20 PREDICATES      96 URIs      88 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.leu.2401158 schema:about N0ff5b97252ba4bad97bf33b7c84931de
2 N3033ae3d82924bcbad539c9e175dd400
3 N37c97f989b7c4cf6bd7b0fcfe99de7d7
4 N3fbe9766225140ffa08823ab9f25139e
5 N42c67bc60d2645609f92ec0930609aa3
6 N49d4f60ad16047198f1f8f000e56a874
7 N54a8256eb9294dc1a6f59b3bd5cad1af
8 N6fddd6fc30624615b42d1943f29fde02
9 N750da9c90df74e1e9011df15726a066a
10 N786a80e4ca4d4427ba9210a1dad9c1b7
11 N8063e63ec4f84808b875711845eead90
12 Na6579e4ff1f6471e8b1a7bee919dddb1
13 Nac7008b4edf3432e8f24e89cbb2f0d39
14 Nb23eaf1b3bcb49559bf701936fc54175
15 Nbd79a59568784b2d99b01aaa87c6e1f0
16 Ne83df8001ba14158b861cdf1d5f9d446
17 anzsrc-for:11
18 anzsrc-for:1103
19 schema:author N3f468ea302224308be9b35bccb296b92
20 schema:datePublished 1998-10-01
21 schema:datePublishedReg 1998-10-01
22 schema:description Prompt empiric antibiotic therapy is of critical importance for patients with neutropenic fever. However, a major concern with important clinical consequences is the emergence of bacterial resistance to antibiotics. After using ceftazidime with a glycopeptide as initial empiric therapy for neutropenic fever, we were confronted with a 75% reduced susceptibility rate to ceftazidime of inducible Enterobacteriaceae collected in 1994. The initial empiric therapy was therefore replaced in May 1995 by a combination of cefepime with amikacin, with addition of a glycopeptide after 48 h if necessary. After this change, we observed a significant decrease in reduced susceptibility of inducible Enterobacteriaceae, not only to ceftazidime, but also to amikacin, cotrimoxazole and ciprofloxacin. There was also a decrease in reduced susceptibility of non-inducible Enterobacteriaceae, such as Klebsiella spp, to ceftazidime. The reduction of resistance may be related at least in part to the combined use of cefepime together with an aminoglycoside. This study shows that it is possible to reverse bacterial resistance by modifying the antibiotic regimen used.
23 schema:genre article
24 schema:isAccessibleForFree false
25 schema:isPartOf N605cfcd38d8149d6befcee8239fc0ac0
26 N8ebca4293e7c46fcb2a1fee87580923f
27 sg:journal.1097065
28 schema:keywords Enterobacteriaceae
29 Klebsiella spp
30 addition
31 amikacin
32 aminoglycosides
33 antibiotic combination therapy
34 antibiotic regimen
35 antibiotic resistance
36 antibiotic therapy
37 antibiotics
38 bacterial resistance
39 cefepime
40 ceftazidime
41 changes
42 ciprofloxacin
43 clinical consequences
44 combination
45 combination of cefepime
46 combination therapy
47 concern
48 consequences
49 cotrimoxazole
50 critical importance
51 decrease
52 emergence
53 empiric antibiotic therapy
54 empiric therapy
55 fever
56 fever patients
57 glycopeptides
58 importance
59 important clinical consequences
60 inducible Enterobacteriaceae
61 initial empiric therapy
62 major concern
63 neutropenic fever
64 neutropenic fever patients
65 part
66 patients
67 prompt empiric antibiotic therapy
68 rate
69 reduced susceptibility
70 reduced susceptibility rates
71 reduction
72 reduction of resistance
73 regimen
74 resistance
75 significant decrease
76 spp
77 study
78 susceptibility
79 susceptibility rates
80 therapy
81 use
82 use of cefepime
83 schema:name Decreasing antibiotic resistance of Enterobacteriaceae by introducing a new antibiotic combination therapy for neutropenic fever patients
84 schema:pagination 1627-1629
85 schema:productId N42474da3fbd44db9aee1e8e8c6a82cf7
86 N602b5886e395429eb652b733cad9b397
87 N73d0474c04d04f25a813e9b7dba37fee
88 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044691809
89 https://doi.org/10.1038/sj.leu.2401158
90 schema:sdDatePublished 2022-12-01T06:20
91 schema:sdLicense https://scigraph.springernature.com/explorer/license/
92 schema:sdPublisher N4583b69a76754a63a2d10d121291215e
93 schema:url https://doi.org/10.1038/sj.leu.2401158
94 sgo:license sg:explorer/license/
95 sgo:sdDataset articles
96 rdf:type schema:ScholarlyArticle
97 N0e0d948622da41969062ae40ad3e6785 rdf:first sg:person.01107322752.01
98 rdf:rest Na72e3cc8718e4e43bb6cc57069db135f
99 N0ff5b97252ba4bad97bf33b7c84931de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Amikacin
101 rdf:type schema:DefinedTerm
102 N1ab643c01cc246fd936925f28b5a2aee schema:affiliation grid-institutes:grid.411414.5
103 schema:familyName Meeus
104 schema:givenName I
105 rdf:type schema:Person
106 N3033ae3d82924bcbad539c9e175dd400 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Enterobacteriaceae
108 rdf:type schema:DefinedTerm
109 N37c97f989b7c4cf6bd7b0fcfe99de7d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Adult
111 rdf:type schema:DefinedTerm
112 N37fe32034114475e8503dd40a8504bfd rdf:first Nb966a112cbb343c1a5846a1ce0af3778
113 rdf:rest N0e0d948622da41969062ae40ad3e6785
114 N3f468ea302224308be9b35bccb296b92 rdf:first sg:person.0773342364.50
115 rdf:rest N9b019078ab8f4e999ba36e3ff2b4914b
116 N3fbe9766225140ffa08823ab9f25139e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Cefepime
118 rdf:type schema:DefinedTerm
119 N42474da3fbd44db9aee1e8e8c6a82cf7 schema:name dimensions_id
120 schema:value pub.1044691809
121 rdf:type schema:PropertyValue
122 N42c67bc60d2645609f92ec0930609aa3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Drug Therapy, Combination
124 rdf:type schema:DefinedTerm
125 N4583b69a76754a63a2d10d121291215e schema:name Springer Nature - SN SciGraph project
126 rdf:type schema:Organization
127 N49d4f60ad16047198f1f8f000e56a874 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Enterobacteriaceae Infections
129 rdf:type schema:DefinedTerm
130 N54a8256eb9294dc1a6f59b3bd5cad1af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Humans
132 rdf:type schema:DefinedTerm
133 N602b5886e395429eb652b733cad9b397 schema:name pubmed_id
134 schema:value 9766509
135 rdf:type schema:PropertyValue
136 N605cfcd38d8149d6befcee8239fc0ac0 schema:volumeNumber 12
137 rdf:type schema:PublicationVolume
138 N6f426edeb96a46e68c33f541462bc40a rdf:first sg:person.0653223122.50
139 rdf:rest N91ddaf50a97b4276a64a71a1679ac94d
140 N6fddd6fc30624615b42d1943f29fde02 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Drug Resistance, Microbial
142 rdf:type schema:DefinedTerm
143 N73d0474c04d04f25a813e9b7dba37fee schema:name doi
144 schema:value 10.1038/sj.leu.2401158
145 rdf:type schema:PropertyValue
146 N750da9c90df74e1e9011df15726a066a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Cephalosporins
148 rdf:type schema:DefinedTerm
149 N786a80e4ca4d4427ba9210a1dad9c1b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Fever
151 rdf:type schema:DefinedTerm
152 N8063e63ec4f84808b875711845eead90 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Hematologic Diseases
154 rdf:type schema:DefinedTerm
155 N8bcd5b9b34114e65affccc81d3a69a91 rdf:first sg:person.01056520727.87
156 rdf:rest N6f426edeb96a46e68c33f541462bc40a
157 N8ebca4293e7c46fcb2a1fee87580923f schema:issueNumber 10
158 rdf:type schema:PublicationIssue
159 N91ddaf50a97b4276a64a71a1679ac94d rdf:first sg:person.0715102045.57
160 rdf:rest rdf:nil
161 N9b019078ab8f4e999ba36e3ff2b4914b rdf:first sg:person.0711125233.20
162 rdf:rest N37fe32034114475e8503dd40a8504bfd
163 Na6579e4ff1f6471e8b1a7bee919dddb1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Teicoplanin
165 rdf:type schema:DefinedTerm
166 Na72e3cc8718e4e43bb6cc57069db135f rdf:first N1ab643c01cc246fd936925f28b5a2aee
167 rdf:rest N8bcd5b9b34114e65affccc81d3a69a91
168 Nac7008b4edf3432e8f24e89cbb2f0d39 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Microbial Sensitivity Tests
170 rdf:type schema:DefinedTerm
171 Nb23eaf1b3bcb49559bf701936fc54175 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Vancomycin
173 rdf:type schema:DefinedTerm
174 Nb966a112cbb343c1a5846a1ce0af3778 schema:affiliation grid-institutes:grid.411414.5
175 schema:familyName Bruyneel
176 schema:givenName P
177 rdf:type schema:Person
178 Nbd79a59568784b2d99b01aaa87c6e1f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Neutropenia
180 rdf:type schema:DefinedTerm
181 Ne83df8001ba14158b861cdf1d5f9d446 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Ceftazidime
183 rdf:type schema:DefinedTerm
184 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
185 schema:name Medical and Health Sciences
186 rdf:type schema:DefinedTerm
187 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
188 schema:name Clinical Sciences
189 rdf:type schema:DefinedTerm
190 sg:journal.1097065 schema:issn 0887-6924
191 1476-5551
192 schema:name Leukemia
193 schema:publisher Springer Nature
194 rdf:type schema:Periodical
195 sg:person.01056520727.87 schema:affiliation grid-institutes:grid.411414.5
196 schema:familyName Van Droogenbroeck
197 schema:givenName J
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01056520727.87
199 rdf:type schema:Person
200 sg:person.01107322752.01 schema:affiliation grid-institutes:grid.411414.5
201 schema:familyName Sion
202 schema:givenName JP
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01107322752.01
204 rdf:type schema:Person
205 sg:person.0653223122.50 schema:affiliation grid-institutes:grid.411414.5
206 schema:familyName Schroyens
207 schema:givenName W
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653223122.50
209 rdf:type schema:Person
210 sg:person.0711125233.20 schema:affiliation grid-institutes:grid.411414.5
211 schema:familyName Goossens
212 schema:givenName H
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711125233.20
214 rdf:type schema:Person
215 sg:person.0715102045.57 schema:affiliation grid-institutes:grid.411414.5
216 schema:familyName Berneman
217 schema:givenName ZN
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0715102045.57
219 rdf:type schema:Person
220 sg:person.0773342364.50 schema:affiliation grid-institutes:grid.411414.5
221 schema:familyName Mebis
222 schema:givenName J
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773342364.50
224 rdf:type schema:Person
225 grid-institutes:grid.411414.5 schema:alternateName Central Pharmacy, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium
226 Division of Hematology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium
227 Division of Hospital Hygiene, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium
228 Laboratory of Microbiology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium
229 schema:name Central Pharmacy, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium
230 Division of Hematology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium
231 Division of Hospital Hygiene, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium
232 Laboratory of Microbiology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium
233 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...